Takeda Pharmaceutical Company (TAK) has released an update.
Takeda Pharmaceutical Company Limited, a leading biopharmaceutical company, announced the pricing of its 2nd Unsecured, Interest Deferrable and Early Redeemable Subordinated Bonds at JPY 460 billion. The bonds, set to mature in 2084, will primarily fund the redemption of Takeda’s 1st Hybrid Bonds due in October 2024. This strategic financial maneuver underscores Takeda’s commitment to leveraging its financial instruments to sustain its growth and development in the pharmaceutical industry.
For further insights into TAK stock, check out TipRanks’ Stock Analysis page.
